United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 2gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - cyclophosphamide monohydrate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - cyclophosphamide monohydrate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - cyclophosphamide monohydrate - powder for solution for injection - 1gram

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide anhydrous 495 g in 500 g

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - cyclophosphamide monohydrate - powder for solution for injection - cyclophosphamide monohydrate 1000 mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - cyclophosphamide monohydrate - coated tablets - 50 milligram - cyclophosphamide

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - cyclophosphamide - coated tablet - cyclophosphamide 50 mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide monohydrate, quantity: 1.069 g (equivalent: cyclophosphamide monohydrate, qty 1 g) - injection, powder for - excipient ingredients: - frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter's staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *modified as the international staging classification for hodgkin's disease in 'report of the committee on the staging of hodgkin's disease'. cancer res 26: 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or waldeyer's ring. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer's ring. all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms. frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung. immunosuppressive properties: cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.